| Ms Maren J Dunn Chandler, DO | |
|
334 Town Center Ave, Big Sky, MT 59716-1713 | |
| (406) 995-6995 | |
| Not Available |
| Full Name | Ms Maren J Dunn Chandler |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 19 Years |
| Location | 334 Town Center Ave, Big Sky, Montana |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376538512 | NPI | - | NPPES |
| 1376538512 | Medicaid | MT | |
| 807252900 | Medicaid | ID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 11561 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Big Sky Medical Center | Big sky, MT | Hospital |
| Bozeman Health Deaconess Hospital | Bozeman, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bozeman Health Big Sky Medical Center Llc | 7315256872 | 8 |
News Archive
Entos Pharmaceuticals (Entos), a healthcare biotechnology company that develops next generation nucleic acid medicines using the Fusogenix drug delivery platform, today announced a collaboration with EpiVax, Inc. (EpiVax), a world leading informatics and immunology biotechnology company with a proven track record in vaccine development.
UT Southwestern Medical Center researchers are conducting two pilot clinical trials to determine whether a single, early dose of estrogen can improve survival and neurological outcomes after severe traumatic brain injury or traumatic hemorrhagic shock.
Merck is pleased to announce that New Brunswick, Nova Scotia and Alberta are the first provinces in Canada to reimburse SIMPONI(golimumab) for the treatment of three different rheumatic conditions. SIMPONI, a subcutaneous anti-tumor necrosis factor therapy, is now reimbursed by the drug formularies of these three provinces for people living with moderately to severely active rheumatoid arthritis, moderately to severely active psoriatic arthritis and active ankylosing spondylitis.
A new report to be presented at the Toronto International AIDS Conference shows that access to antiretrovirals is only part of the treatment equation.
Streptococcus pneumoniae likely is not a term immediately recognizable by most individuals, even if they have had unpleasant run-ins with the common bacterium. However, experts at Mississippi State University are pioneering pathways to new treatment options.
› Verified 3 days ago
| Entity Name | Community Health Partners Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487741005 PECOS PAC ID: 5799681482 Enrollment ID: O20031211001095 |
News Archive
Entos Pharmaceuticals (Entos), a healthcare biotechnology company that develops next generation nucleic acid medicines using the Fusogenix drug delivery platform, today announced a collaboration with EpiVax, Inc. (EpiVax), a world leading informatics and immunology biotechnology company with a proven track record in vaccine development.
UT Southwestern Medical Center researchers are conducting two pilot clinical trials to determine whether a single, early dose of estrogen can improve survival and neurological outcomes after severe traumatic brain injury or traumatic hemorrhagic shock.
Merck is pleased to announce that New Brunswick, Nova Scotia and Alberta are the first provinces in Canada to reimburse SIMPONI(golimumab) for the treatment of three different rheumatic conditions. SIMPONI, a subcutaneous anti-tumor necrosis factor therapy, is now reimbursed by the drug formularies of these three provinces for people living with moderately to severely active rheumatoid arthritis, moderately to severely active psoriatic arthritis and active ankylosing spondylitis.
A new report to be presented at the Toronto International AIDS Conference shows that access to antiretrovirals is only part of the treatment equation.
Streptococcus pneumoniae likely is not a term immediately recognizable by most individuals, even if they have had unpleasant run-ins with the common bacterium. However, experts at Mississippi State University are pioneering pathways to new treatment options.
› Verified 3 days ago
| Entity Name | Bozeman Health Big Sky Medical Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740659952 PECOS PAC ID: 7315256872 Enrollment ID: O20151023000110 |
News Archive
Entos Pharmaceuticals (Entos), a healthcare biotechnology company that develops next generation nucleic acid medicines using the Fusogenix drug delivery platform, today announced a collaboration with EpiVax, Inc. (EpiVax), a world leading informatics and immunology biotechnology company with a proven track record in vaccine development.
UT Southwestern Medical Center researchers are conducting two pilot clinical trials to determine whether a single, early dose of estrogen can improve survival and neurological outcomes after severe traumatic brain injury or traumatic hemorrhagic shock.
Merck is pleased to announce that New Brunswick, Nova Scotia and Alberta are the first provinces in Canada to reimburse SIMPONI(golimumab) for the treatment of three different rheumatic conditions. SIMPONI, a subcutaneous anti-tumor necrosis factor therapy, is now reimbursed by the drug formularies of these three provinces for people living with moderately to severely active rheumatoid arthritis, moderately to severely active psoriatic arthritis and active ankylosing spondylitis.
A new report to be presented at the Toronto International AIDS Conference shows that access to antiretrovirals is only part of the treatment equation.
Streptococcus pneumoniae likely is not a term immediately recognizable by most individuals, even if they have had unpleasant run-ins with the common bacterium. However, experts at Mississippi State University are pioneering pathways to new treatment options.
› Verified 3 days ago
| Entity Name | Bozeman Health Big Sky Medical Center Llc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1588141048 PECOS PAC ID: 7315256872 Enrollment ID: O20181114003365 |
News Archive
Entos Pharmaceuticals (Entos), a healthcare biotechnology company that develops next generation nucleic acid medicines using the Fusogenix drug delivery platform, today announced a collaboration with EpiVax, Inc. (EpiVax), a world leading informatics and immunology biotechnology company with a proven track record in vaccine development.
UT Southwestern Medical Center researchers are conducting two pilot clinical trials to determine whether a single, early dose of estrogen can improve survival and neurological outcomes after severe traumatic brain injury or traumatic hemorrhagic shock.
Merck is pleased to announce that New Brunswick, Nova Scotia and Alberta are the first provinces in Canada to reimburse SIMPONI(golimumab) for the treatment of three different rheumatic conditions. SIMPONI, a subcutaneous anti-tumor necrosis factor therapy, is now reimbursed by the drug formularies of these three provinces for people living with moderately to severely active rheumatoid arthritis, moderately to severely active psoriatic arthritis and active ankylosing spondylitis.
A new report to be presented at the Toronto International AIDS Conference shows that access to antiretrovirals is only part of the treatment equation.
Streptococcus pneumoniae likely is not a term immediately recognizable by most individuals, even if they have had unpleasant run-ins with the common bacterium. However, experts at Mississippi State University are pioneering pathways to new treatment options.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Maren J Dunn Chandler, DO 334 Town Center Ave, Big Sky, MT 59716-1713 Ph: (406) 995-6995 | Ms Maren J Dunn Chandler, DO 334 Town Center Ave, Big Sky, MT 59716-1713 Ph: (406) 995-6995 |
News Archive
Entos Pharmaceuticals (Entos), a healthcare biotechnology company that develops next generation nucleic acid medicines using the Fusogenix drug delivery platform, today announced a collaboration with EpiVax, Inc. (EpiVax), a world leading informatics and immunology biotechnology company with a proven track record in vaccine development.
UT Southwestern Medical Center researchers are conducting two pilot clinical trials to determine whether a single, early dose of estrogen can improve survival and neurological outcomes after severe traumatic brain injury or traumatic hemorrhagic shock.
Merck is pleased to announce that New Brunswick, Nova Scotia and Alberta are the first provinces in Canada to reimburse SIMPONI(golimumab) for the treatment of three different rheumatic conditions. SIMPONI, a subcutaneous anti-tumor necrosis factor therapy, is now reimbursed by the drug formularies of these three provinces for people living with moderately to severely active rheumatoid arthritis, moderately to severely active psoriatic arthritis and active ankylosing spondylitis.
A new report to be presented at the Toronto International AIDS Conference shows that access to antiretrovirals is only part of the treatment equation.
Streptococcus pneumoniae likely is not a term immediately recognizable by most individuals, even if they have had unpleasant run-ins with the common bacterium. However, experts at Mississippi State University are pioneering pathways to new treatment options.
› Verified 3 days ago
Dr. Philip Alan Hess, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 334 Town Center Ave, Big Sky, MT 59716 Phone: 406-995-6995 | |
Dr. Lehman Clark Sammons Jr., MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 100 Beaverhead Trail, Big Sky, MT 59716 Phone: 406-993-2797 Fax: 406-995-2965 | |
Kevin Curtis Sullivan, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 334 Town Center Ave, Big Sky, MT 59715 Phone: 406-995-6995 | |
Jeremy Philip Mitchell, DO Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 334 Town Center Ave, Big Sky, MT 59716 Phone: 406-995-6995 |